QuidelOrtho Corp. Stock
€25.80
Your prediction
QuidelOrtho Corp. Stock
Pros and Cons of QuidelOrtho Corp. in the next few years
Pros
Cons
Performance of QuidelOrtho Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
QuidelOrtho Corp. | -5.110% | 6.612% | 4.878% | -35.500% | -38.571% | -64.658% | -87.944% |
Veeva Systems A | -0.320% | 2.098% | 9.142% | 35.783% | 24.557% | 45.126% | 7.110% |
Thermo Fisher Scientific Inc. | 0.610% | 16.543% | 9.944% | -15.217% | -7.450% | -16.338% | 20.871% |
Waters Corp. | 2.290% | 12.400% | 7.113% | -12.139% | -21.232% | -1.025% | 67.725% |
Comments
News

QuidelOrtho (QDEL) Fiscal Q2 EPS Beats
QuidelOrtho (NASDAQ:QDEL), a global provider of diagnostic testing solutions, released its financial results for the quarter ended June 29, 2025, on August 5, 2025. The most notable headline was a

QuidelOrtho to Participate in Upcoming Investor Conferences
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine

QuidelOrtho Reports First Quarter 2025 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and